Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immuron Ltd ADR (IMRN)

Immuron Ltd ADR (IMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,769
  • Shares Outstanding, K 5,729
  • Annual Sales, $ 3,220 K
  • Annual Income, $ -4,550 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.38
  • Price/Sales 3.40
  • Price/Cash Flow N/A
  • Price/Book 1.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7334 +8.45%
on 11/13/24
2.1100 -10.91%
on 11/05/24
-0.1220 (-6.09%)
since 10/22/24
3-Month
1.7334 +8.45%
on 11/13/24
2.8700 -34.50%
on 09/04/24
-0.8901 (-32.13%)
since 08/22/24
52-Week
1.5900 +18.23%
on 02/01/24
5.9600 -68.46%
on 03/07/24
+0.0799 (+4.44%)
since 11/22/23

Most Recent Stories

More News
Immuron Limited Announces Participation in the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 11:00 PTMelbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical...

IMRN : 1.8799 (-1.53%)
Immuron Limited Announces Participation in the LD Micro Invitational XIII

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset...

IMRN : 1.8799 (-1.53%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.075 (unch)
SILO : 0.8600 (-5.49%)
LLY : 748.01 (-0.25%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6800 (-4.37%)
IMRN : 1.8799 (-1.53%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 0.8600 (-5.49%)
LLY : 748.01 (-0.25%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6800 (-4.37%)
IMRN : 1.8799 (-1.53%)
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic

MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)
Immuron North American Travelan® Sales up 494% and Global sales up 431%

Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by...

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical...

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)
US Department of Defense Uniformed Services University Clinical Evaluation of Travelanâ„¢

UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU)....

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 1.8799 (-1.53%)
IMC.AX : 0.075 (unch)

Business Summary

Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale,...

See More

Key Turning Points

3rd Resistance Point 2.0365
2nd Resistance Point 1.9732
1st Resistance Point 1.9266
Last Price 1.8799
1st Support Level 1.8167
2nd Support Level 1.7534
3rd Support Level 1.7068

See More

52-Week High 5.9600
Fibonacci 61.8% 4.2907
Fibonacci 50% 3.7750
Fibonacci 38.2% 3.2593
Last Price 1.8799
52-Week Low 1.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar